Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.